Projects / Programmes source: ARRS

Development of Mur Ligase Inhibitors as Novel Antibacterial Agents     

Research activity

Code Science Field Subfield
1.09.00  Natural sciences and mathematics  Pharmacy   

Code Science Field
B740  Biomedical sciences  Pharmacological sciences, pharmacognosy, pharmacy, toxicology 
P390  Natural sciences and mathematics  Organic chemistry 
P310  Natural sciences and mathematics  Proteins, enzymology 
B230  Biomedical sciences  Microbiology, bacteriology, virology, mycology 
novel antibacterial agents, inhibitors, Mur ligases
Evaluation (rules)
source: COBISS
Researchers (2)
no. Code Name and surname Research area Role Period No. of publications
1.  20372  PhD Petra Štefanič  Pharmacy  Researcher  2005 - 2007  32 
2.  01878  PhD Uroš Urleb  Pharmacy  Principal Researcher  2005 - 2007  379 
Organisations (1)
no. Code Research organisation City Registration number No. of publications
1.  0258  Lek Pharmaceutical Company d.d.  Ljubljana  1732811  9,974 
The main purpose of the research project is the development of novel antibacterial agents. In order to challenge the infections caused by resistant bacterial strains novel targets are considered, among which the enzymes of bacterial cell wall synthesis Mur ligases are considered as most promising ones. Already published basic mechanistic features and crystal structures of Mur ligase enzymes as well as few known Mur inhibitors will give the starting point for development of novel potent Mur ligase inhibitors. Various modern techniques of rational drug design and organic synthesis will be applied in order to develop drug-like Mur ligase inhibitor candidate for clinical trials.
Views history